论文部分内容阅读
目的比较血液透析与腹膜透析对进入终末期肾病(ESRD)的常染色体显性多囊肾病(ADPKD)患者预后的影响。方法回顾性分析自1999年3月至2014年8月第二军医大学附属长海医院肾内科收治的43例ADPKD患者的临床资料。根据初始透析方法的不同,将43例患者分为血液腹膜透析组(n=20)及血液透析组(n=23)。随访期间,记录心血管事件发生情况,并对两组患者心血管事件发生率进行比较。以全因死亡为终点事件,绘制生存曲线,采用Kaplan Meier法和LogRank检验对两组患者存活率进行比较。结果本研究共43例患者,最长随访147个月。腹膜透析组心血管事件发生率5.0%(1/20),血液透析组26.1%(6/23),两组间比较,差异有统计学意义(P<0.01)。随访期内,腹膜透析组患者,存活率85.0%(17/20),血液透析组存活率73.9%(17/23),两组间比较,差异无统计学意义(P>0.05)。结论腹膜透析与血液透析均是ADPKD肾衰竭患者的有效肾替代治疗方法。与腹膜透析比较,血液透析患者心血管事件发生概率较低。
Objective To compare the effects of hemodialysis and peritoneal dialysis on the prognosis of patients with autosomal dominant polycystic kidney disease (ADPKD) entering end-stage renal disease (ESRD). Methods The clinical data of 43 ADPKD patients admitted to Changhai Hospital, Second Military Medical University from March 1999 to August 2014 were retrospectively analyzed. According to the initial dialysis method, 43 patients were divided into blood peritoneal dialysis group (n = 20) and hemodialysis group (n = 23). During follow-up, the incidence of cardiovascular events was recorded and the incidence of cardiovascular events was compared between the two groups. Survival rate was compared between the two groups using Kaplan-Meier method and LogRank test. Results A total of 43 patients were followed up for a maximum of 147 months. Peritoneal dialysis group, the incidence of cardiovascular events 5.0% (1/20), hemodialysis group 26.1% (6/23), between the two groups, the difference was statistically significant (P <0.01). During the follow-up period, the survival rate of peritoneal dialysis group was 85.0% (17/20) and that of hemodialysis group was 73.9% (17/23). There was no significant difference between the two groups (P> 0.05). Conclusion Peritoneal dialysis and hemodialysis are effective renal replacement therapy in patients with ADPKD renal failure. Compared with peritoneal dialysis, hemodialysis patients have a lower probability of cardiovascular events.